Why Is RNA Therapeutics-Focused Avidity Biosciences Stock Trading Higher Today?
Portfolio Pulse from Vandana Singh
Avidity Biosciences Inc (RNA) announced a collaboration with Bristol Myers Squibb (BMY) to develop and commercialize cardiovascular targets, with potential payments up to $2.3 billion. Avidity will receive $100 million upfront, including a $60 million cash payment and a $40 million stock purchase by BMY at $7.88 per share. The deal includes up to $1.35 billion in R&D milestones, $825 million in commercial milestones, and royalties on net sales. BMY will fund all future activities for the collaboration. RNA shares surged 28.4% in premarket trading.
November 28, 2023 | 2:17 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Bristol Myers Squibb enters a collaboration with RNA to develop cardiovascular targets, with BMY funding future activities and RNA receiving up to $2.3 billion in payments.
While the collaboration is a positive strategic move for BMY, the financial impact is relatively smaller compared to the overall size of the company. The commitment to fund future activities is typical for such deals and is unlikely to significantly impact BMY's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Avidity Biosciences announced a significant collaboration with BMY, including a $100 million upfront payment and potential for $2.3 billion in milestones and royalties. RNA's stock price rose 28.4% in premarket trading.
The announcement of the collaboration with BMY is a significant positive development for RNA, indicating a strong validation of its technology and providing substantial financial benefits. The upfront payment and potential milestone payments are likely to be viewed positively by investors, leading to an increase in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 95
RELEVANCE 100